ATE494306T1 - Humanisierte anti-cd100-antikörper - Google Patents

Humanisierte anti-cd100-antikörper

Info

Publication number
ATE494306T1
ATE494306T1 AT08729737T AT08729737T ATE494306T1 AT E494306 T1 ATE494306 T1 AT E494306T1 AT 08729737 T AT08729737 T AT 08729737T AT 08729737 T AT08729737 T AT 08729737T AT E494306 T1 ATE494306 T1 AT E494306T1
Authority
AT
Austria
Prior art keywords
antibodies
compositions
antigen
antibody
variants
Prior art date
Application number
AT08729737T
Other languages
English (en)
Inventor
Ernest Smith
Terrence Fisher
Maurice Zauderer
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Application granted granted Critical
Publication of ATE494306T1 publication Critical patent/ATE494306T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08729737T 2007-02-14 2008-02-13 Humanisierte anti-cd100-antikörper ATE494306T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90153007P 2007-02-14 2007-02-14
PCT/US2008/053816 WO2008100995A1 (en) 2007-02-14 2008-02-13 Humanized anti-cd100 antibodies

Publications (1)

Publication Number Publication Date
ATE494306T1 true ATE494306T1 (de) 2011-01-15

Family

ID=39535347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08729737T ATE494306T1 (de) 2007-02-14 2008-02-13 Humanisierte anti-cd100-antikörper

Country Status (5)

Country Link
US (1) US7919594B2 (de)
EP (1) EP2069404B1 (de)
AT (1) ATE494306T1 (de)
DE (1) DE602008004296D1 (de)
WO (1) WO2008100995A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) * 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
RU2511406C2 (ru) * 2006-06-08 2014-04-10 Чугаи Сейяку Кабусики Кайся Профилактическое или лекарственное средство для воспалительного заболевания
MY180713A (en) * 2007-09-26 2020-12-07 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN106519025B (zh) * 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR101595134B1 (ko) * 2007-12-05 2016-02-17 추가이 세이야쿠 가부시키가이샤 소양증 치료제
AU2008332271C1 (en) 2007-12-05 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Anti-NR10 antibody and use thereof
PL2708558T3 (pl) 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
EP2282769A4 (de) * 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
KR20170080705A (ko) 2009-05-08 2017-07-10 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
EP2445530B1 (de) * 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Verfahren zur behandlung chronischer lymphozytenleukämie
US8586714B2 (en) * 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
CA2775959A1 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
LT2566517T (lt) 2010-05-04 2019-01-10 Five Prime Therapeutics, Inc. Antikūnai, surišantys csf1r
AU2011285852B2 (en) * 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
KR102003571B1 (ko) * 2011-05-13 2019-07-24 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 골형성 촉진제
KR101999872B1 (ko) 2011-10-11 2019-07-12 백시넥스 인코포레이티드 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
ES2837826T3 (es) 2012-05-30 2021-07-01 Univ Rowan Terapia metabólica para el estrés oxidativo en el cerebro a través del catabolismo neuronal direccionado del ácido N-acetil-aspártico
TWI713436B (zh) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
EP2970459A2 (de) 2013-03-15 2016-01-20 AbbVie Inc. Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
WO2014209802A1 (en) * 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
JP6797801B2 (ja) 2014-12-22 2020-12-09 ファイヴ プライム セラピューティクス インク Ｐｖｎｓを治療するための抗ｃｓｆ１ｒ抗体
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
JP7128177B2 (ja) 2016-08-02 2022-08-30 バクシネックス インコーポレーティッド ワクシニアウイルス／真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法
EP3600419B1 (de) * 2017-03-20 2023-08-09 Vaccinex, Inc. Behandlung von krebs mit einem semaphorin-4d-antikörper in kombination mit einem epigenetischen modulierungsmittel
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン４ｄ抗体
BR112020004879A2 (pt) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
KR102614472B1 (ko) 2019-03-28 2023-12-14 백시넥스 인코포레이티드 암 요법에 사용하기 위한 세마포린-4d 길항제
MX2021015970A (es) 2019-06-21 2022-04-06 Vaccinex Inc Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1.
EP4007774A1 (de) 2019-08-01 2022-06-08 Vaccinex, Inc. Kombinierte hemmung von semaphorin-4d und tgfb und zusammensetzungen dafür
AU2020387034A1 (en) 2019-11-20 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
EP4172205A1 (de) 2020-06-25 2023-05-03 Vaccinex, Inc. Verwendung von semaphorin-4d-bindenden molekülen zur behandlung des rett-syndroms
EP4251748A1 (de) * 2020-11-30 2023-10-04 Merck Sharp & Dohme LLC Arginase-1-bindemittel zur hemmung der arginase-1-aktivität
KR20240063995A (ko) 2021-09-27 2024-05-10 백시넥스 인코포레이티드 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링
WO2023154906A1 (en) 2022-02-13 2023-08-17 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
CN117866091A (zh) * 2022-10-12 2024-04-12 三优生物医药(上海)有限公司 抗cd100抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
EP1442749A1 (de) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von einem Antikörper gegen CD100 für die Diagnose und die Behandlung von einer entzündlichen Krankheit des Zentralnervensystems
JP2008535856A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および治療におけるｓｅｍａ４ｄ

Also Published As

Publication number Publication date
US7919594B2 (en) 2011-04-05
US20080219971A1 (en) 2008-09-11
EP2069404B1 (de) 2011-01-05
DE602008004296D1 (de) 2011-02-17
WO2008100995A1 (en) 2008-08-21
EP2069404A1 (de) 2009-06-17

Similar Documents

Publication Publication Date Title
ATE494306T1 (de) Humanisierte anti-cd100-antikörper
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
HUS2200044I1 (hu) Humanizált anti-CD19 ellenanyagok és használatuk daganatokban, transzplantációknál és autoimmun betegségekben
CY1122270T1 (el) Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων
JP2013519375A5 (de)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EA200901533A1 (ru) Антитела il-6 и их применение
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
NZ610734A (en) Human antibodies to the glucagon receptor
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
MY157173A (en) Modified humanised anti-interleukin-18
EP1996716A4 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
MX2009012493A (es) Metodos de humanizacion de anticuerpo de conejo novedosos y anticuerpos de conejo humanizados.
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2013227339A5 (de)
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
NZ594682A (en) Fully human antibodies specific to cadm1
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
NZ598670A (en) Antibodies against glucagon receptor and their use
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
MY192146A (en) Binding molecules specific for asct2 and uses thereof
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties